| Literature DB >> 30538719 |
Megumi Shigematsu1, Takuya Kawamura1, Yohei Kirino1.
Abstract
Cellular RNA molecules contain phosphate or hydroxyl ends. A 2',3'-cyclic phosphate (cP) is one of the 3'-terminal forms of RNAs mainly generated from RNA cleavage by ribonucleases. Although transcriptome profiling using RNA-seq has become a ubiquitous tool in biological and medical research, cP-containing RNAs (cP-RNAs) form a hidden transcriptome layer, which is infrequently recognized and characterized, because standard RNA-seq is unable to capture them. Despite cP-RNAs' invisibility in RNA-seq data, increasing evidence indicates that they are not accumulated simply as non-functional degradation products; rather, they have physiological roles in various biological processes, designating them as noteworthy functional molecules. This review summarizes our current knowledge of cP-RNA biogenesis pathways and their catalytic enzymatic activities, discusses how the cP-RNA generation affects biological processes, and explores future directions to further investigate cP-RNA biology.Entities:
Keywords: 2′; 3′-cyclic phosphate (cP); angiogenin (ANG); cP-RNA-seq; cP-containing RNA (cP-RNA); non-coding RNA (ncRNA); ribonuclease; tRNA half
Year: 2018 PMID: 30538719 PMCID: PMC6277466 DOI: 10.3389/fgene.2018.00562
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Chemical structures of RNA termini.
FIGURE 2cP formation via RNA cleavage by ribonucleases. (A,B) Cleavage reactions catalyzed by RNase A (A) and ANG (B). (C) Structure of ANG catalytic site (human wild type, PDB ID: 1B1I). Three catalytic residues are shown in pink, and the residues forming a substrate binding pocket and/or associating with Gln117 are shown in green. Orange dotted lines indicate the hydrogen bonds that particularly support Gln117’s obstructive position (Leonidas et al., 1999, 2002; Holloway et al., 2004).
Ribonucleases reported to generate a cP as a final form.
| Ribonuclease | Type | cP-examined organism | Target RNA | Physiological role | Reference validating the cP formation |
|---|---|---|---|---|---|
| ANG | Endo | Human | Mature tRNAs | Production of tRNA halves (tiRNAs, SHOT-RNAs) | |
| IreI | Endo | Human, | Xbp1 mRNA splicing in the UPR pathway | ||
| PP11 | Endo | Human | (not identified) | ||
| Sen2 | Endo | Precursor tRNAs containing an intron | tRNA splicing | ||
| Las1 | Endo | 37S precursor rRNA | rRNA maturation | ||
| GCN4 | Endo | (not identified) | |||
| zymocin (γ-subunit) | Endo | tRNAs-GluUUC, LysUUU, GlnUUG | Toxin to inhibit other yeasts’ growth | ||
| PaT (PaOrf2) | Endo | tRNA-GlnUUG, GlnCUG | Toxin to inhibit other yeasts’ growth | ||
| MazF | Endo | mRNAs, tRNAs, rRNAs | TA system | ||
| ChpBK | Endo | mRNA | TA system | ||
| Colicin E5 | Endo | tRNAs-TyrGUA, HisGUG, AsnGUU, AspGUC | Toxin to kill other bacteria | ||
| Colicin D | Endo | tRNAs-ArgACG,ArgCCG, ArgUCU, ArgCCU | Toxin to kill other bacteria | ||
| prrC | Endo | tRNA-LysUUU | Host defense upon phase infection | ||
| NendoU | Endo | Nidovirus | (not identified) | ||
| Type IB topoisomerase | Endo | Vaccinia virus | (not identified) | ||
| USB1 (MPN1) | Exo | Human | U6 snRNA | U6 snRNA maturation |
FIGURE 3Generation of cP-RNAs in tRNA splicing (A), tiRNA/SHOT-RNA production (B), U6 snRNA maturation (C), the UPR pathway (D), toxin invasions (E), the TA system (F), and the biogenesis of tRNA-derived piRNAs (G).
FIGURE 4Schematic representation of cP-RNA-seq (A) and probe-based RT-qPCR (B) for specific cP-RNA analyses.